SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (1804)12/5/1999 10:53:00 PM
From: DanZ  Read Replies (2) of 5582
 
Come on, Mad2. A press release is a press release. The one that you posted was just issued by Information Access Company. It reads nearly word for word like the press releases on Bloomberg, Reuters, and PRNewswire. Do you have anything else to argue about other than semantics?

Here are some things for you to consider. A joint venture for nicotine gum is coming soon that will greatly increase sales and be accretive to earnings next year. A joint venture for dental gum is coming early next year and will be accretive to earnings in the latter half of 2000. Sales of Zicam will be at least $8 million in the fourth quarter, up over 500% from the third quarter. Gum Tech will be very profitable in the fourth quarter and each quarter thereafter for the foreseeable future. Gum Tech's future is using gum as a delivery system for pharmaceutical drugs. The stock will trade significantly higher in time and the price to sales ratio that so concerns you will decline. That in a nut shell is why GUMM is a lousy long term short, although one can play the volatility to scalp it for short term trades. The longer one holds a short position in this stock, the more likely that they will give back their gains or lose money.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext